Efficacy and Safety of Resveratrol Supplements on Blood Lipid and Blood Glucose Control in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Study answer

What this study found

Resveratrol supplementation may improve insulin resistance and glycemic control in adults with type 2 diabetes: HOMA-IR reduced by 0.99 (95% CI −1.61 to −0.38; P = 0.002); HbA1c reduced by 0.45 percentage points (95% CI −0.73 to −0.16; P = 0.002); fasting glucose reduced by 19.61 mg/dL (95% CI −26.02 to −13.20; P < 0.00001); fasting insulin reduced (SMD −0.67; 95% CI −1.21 to −0.14; P = 0.01). No significant changes in TC (−7.11; 95% CI −16.28 to 2.06; P = 0.13), TG (−2.15; 95% CI −5.52 to 1.22; P = 0.21), or LDL-C (−6.84; 95% CI −16.60 to 2.92; P = 0.17). Adverse events did not differ…

Study & population

Adults with type 2 diabetes mellitus; 15 randomized controlled trials comprising 896 participants; mixed genders; mean ages generally in the 50s–60s; multicountry settings (e.g., Iran, China, Japan, Hungary, Egypt, India, Singapore).

Intervention

Oral resveratrol supplements in capsule form; regimens varied by trial (examples include 100 mg/day, 240 mg BID, 400–500 mg/day, 240 mg BID, 400 mg BID, 500 mg BID, and up to 3000 mg/day in one trial); durations ranged from 1 month to 6 months.

Key limitation

High heterogeneity across trials (I2 up to 95% for several outcomes); small sample sizes in many RCTs; wide variation in resveratrol dose, formulation, and duration; several studies with unclear randomization or blinding; incomplete outcome data in some trials; safety data limited.

View full study detailsView sourceOpen PDF

Original abstract